REG - Medpal AI PLC - Result of AGM

Medpal AIAnnouncement

Yesterday 11:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260330:nRSd6494Ya&default-theme=true

RNS Number : 6494Y  Medpal AI PLC  30 March 2026

30 March 2026

MedPal AI plc

("MedPal AI" or the "Company")

Result of AGM

MedPal AI plc (AIM:MPAL, FRA Z1N), the digital health and AI company,
announces that, at the annual general meeting of the Company held today, all
of the resolutions were passed. The results of the poll vote are set out
below.

 

 Summary of Resolutions                                                          For          Percentage of votes in Favour  Against  Percentage of votes Against  Withheld  Total of issued share capital voted  Percentage of issued share capital voted
 1 Receive the consolidated annual report and accounts for the year ended 31     224,919,529  99.98%                         38,956   0.02%                        116,470   224,958,485                          45.68%
 August 2025
 2 Reappoint Jason Drummond as a director of the Company                         224,809,794  99.95%                         122,314  0.05%                        142,847   224,932,108                          45.68%
 3 Reappoint Kevin O'Neill as a director of the Company                          224,811,214  99.95%                         120,894  0.05%                        142,847   224,932,108                          45.68%
 4 Reappoint Justin Drummond as a director of the Company                        224,869,171  99.97%                         65,279   0.03%                        140,505   224,934,450                          45.68%
 5 Reappoint Adam Monaco as a director of the Company                            224,810,542  99.95%                         121,391  0.05%                        143,022   224,931,933                          45.68%
 6 Reappoint Grant Thornton Limited as auditors                                  224,805,257  99.96%                         100,743  0.04%                        168,955   224,906,000                          45.67%
 7 To authorise the Directors to determine the fees payable to the auditors      224,632,019  99.92%                         190,457  0.08%                        252,479   224,822,476                          45.65%
 8 To authorise the Directors to allot ordinary shares and relevant securities   224,514,082  99.80%                         445,098  0.20%                        115,775   224,959,180                          45.68%
 pursuant to Section 551 of the Companies Act 2006.

 9 To disapply pre-emption rights in certain circumstances (general authority).  224,643,956  99.88%                         271,975  0.12%                        159,024   224,915,931                          45.67%

 

Notes:

A vote "withheld" is not a vote in law and has not been counted as a vote
"for" or "against" a resolution.

Resolutions 1 to 8 were passed as Ordinary Resolutions. Resolution 9 was
passed as a Special Resolution

The number of ordinary shares in issue at the date of this announcement is
492,441,036, of which no ordinary shares are held in treasury.

 

Enquiries:

 MedPal AI plc

 Jason Drummond, Chief Executive Officer     Via Square1 Consulting

 Cairn Financial Advisers LLP                +44 (0) 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Clear Capital Markets Limited               +44 (0) 20 3869 6080

 Bob Roberts

 Square1 Consulting                          +44 (0) 20 7929 5599

 David Bick                                  +44 (0) 7831 381201

 

 

 

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven
wellness management. Its core app aggregates data from over 100 wearables and
health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile,
offering non-clinical, personalised lifestyle guidance through its AI wellness
coach. The Company is also developing conversational AI to provide
voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a
24/7 AI-powered automated pharmacy distribution centre, providing nationwide
NHS and private prescription services. The facility leverages advanced robotic
dispensing technology integrated with AI triage to deliver rapid,
cost-effective medication fulfilment with same-day and next-day delivery
capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms like Siemens and Volvo.
Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare
providers, businesses, and insurers, with potential use in insurance-linked
wellness programs to reduce premiums and drive new revenue through
institutional partnerships. The Company also has a partnership agreement with
Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGBGGDXXBXDGLG



            Copyright 2019 Regulatory News Service, all rights reserved